Compare FLOC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | SGP |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | FLOC | SGP |
|---|---|---|
| Price | $24.78 | $24.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 662.1K | 59.1K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.03 | $20.15 |
| 52 Week High | $25.76 | $30.56 |
| Indicator | FLOC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 47.66 |
| Support Level | $15.04 | $20.95 |
| Resistance Level | N/A | $26.55 |
| Average True Range (ATR) | 0.95 | 1.42 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 65.63 | 52.86 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.